New drug R & D becomes the focus of attention pharmaceutical outsourcing industry will meet the opportunity

Source: Shanghai Securities May 10, 2016 [China Pharmaceutical Market analysis] Nowadays, the development of innovative new drugs has become the focus of attention of pharmaceutical companies With the gradual release of the demand for new drug research and development in China, the reform of the pharmaceutical industry will increase In the next few years, the pharmaceutical R & D outsourcing industry in China may usher in new development opportunities and become an important part of the pharmaceutical R & D industry chain The outsourcing service of medical R & D contract mainly includes the design and consultation of clinical trial scheme and case report form, data management, statistical analysis and writing of statistical analysis report, which is a kind of outsourcing service with high professional requirements The pharmaceutical R & D outsourcing industry mainly relies on undertaking new drug R & D outsourcing contracts of large pharmaceutical enterprises to achieve profits The service scope basically covers all stages and fields of new drug research and development For most pharmaceutical companies, some or all of them entrust pharmaceutical R & D outsourcing companies to be the inevitable choice of modern professional division of labor, which will be more professional, more effective and reduce pharmaceutical costs As the most developed region in the pharmaceutical R & D outsourcing market, Europe and the United States occupy the main share of the global pharmaceutical R & D outsourcing market Nine of the top 10 pharmaceutical R & D outsourcing companies in the world come from Europe and the United States According to BCG and icon, the market scale of pharmaceutical R & D outsourcing in 2013 was US $28 billion, and the share of R & D outsourcing accounted for 47% of the market share of the industry In 2020, the market size is expected to reach 40 billion US dollars, and the penetration rate is expected to exceed 55% At present, China has surpassed India as the first choice of R & D outsourcing in Asia With the increasing cost pressure, pharmaceutical R & D outsourcing has become an important element of competition among large pharmaceutical enterprises In recent years, in order to reduce the cost of drug research and development, pharmaceutical giants have accelerated the transfer of biomedical research to emerging markets in Asia In the next few years, the growth rate of Asia's emerging markets will continue to increase, which is expected to bring great development opportunities to China The development of pharmaceutical R & D outsourcing market depends on the demand for new drug R & D China's pharmaceutical R & D outsourcing started late, the pharmaceutical market is dominated by generic drugs, and the power of new drug R & D is insufficient With the increasing support policies, the pharmaceutical R & D outsourcing industry is expected to usher in rapid development In March this year, the general office of the State Council issued the opinions on the evaluation of the consistency of quality and efficacy of generic drugs, making arrangements for the evaluation of the consistency of quality and efficacy of generic drugs approved for marketing On March 28, the State Food and Drug Administration formulated the procedures for conformity assessment of quality and efficacy of generic drugs (Draft for comments) and the requirements for application materials for conformity assessment of chemical generic oral solid preparations (Draft for comments) The implementation of "consistency evaluation" will enhance the overall level of China's pharmaceutical industry, promote the upgrading and structural adjustment of the pharmaceutical industry, improve the innovation ability of China's pharmaceutical industry, and bring incremental demand for the pharmaceutical R & D outsourcing industry With the rapid release of China's demand for innovative drug research and development, it is expected that by 2018, the scale of China's pharmaceutical research and development outsourcing market will exceed 60 billion yuan The organization believes that the pharmaceutical R & D outsourcing industry in China will enhance the degree of service specialization, open up the upstream and downstream links, expand the business scope and achieve vertical integration In the future, the industry will form a large-scale and professional pharmaceutical R & D outsourcing company through M & A in resource integration, pharmaceutical R & D outsourcing companies that have occupied market resources will take the lead to benefit.